PRESS & NEWS
Registry data reveal which FTD subtypes and genes have the highest representation of research-ready participants, helping scientists design stronger, more focused studies.
more >
Alector has announced topline results from its Phase 3 INFRONT-3 trial of latozinemab for FTD-GRN.
more >
Life with FTD is about so much more than medical symptoms. To better understand the impact of FTD disorders, our September Quick Question asked …
more >
Progress is possible. See how Registry data can unlock breakthroughs in FTD research just as new treatments are showing progress in other neurological disorders.
more >
Only a fraction of people with FTD and their relatives pursue genetic testing. This World FTD Awareness Week, discover how genetic counseling can guide the way.
more >Together we can find a cure for ftd
The FTD Disorders Registry is a powerful tool in the movement to create therapies and find a cure. Together we can help change the course of the disease and put an end to FTD.
Your privacy is important! We promise to protect it. We will not share your contact information.